JPMorgan downgrades Teva as generic medication business struggles

JPMorgan downgrades Teva as generic medication business struggles

Teva Pharmaceutical is hard to like as it continues to be weighed down by underperformance in some business areas, JPMorgan says. Analyst Chris Schott downgraded the stock to underweight from neutral and lowered his price target to $10 from $11, as he remains unconvinced of a long-term growth story when stacked against other pharmaceutical names. … Read more

Omicron subvariants resistant to key antibody treatments are increasing every week in the U.S.

Omicron subvariants resistant to key antibody treatments are increasing every week in the U.S.

Two omicron subvariants that are resistant to key antibody treatments are on the rise in the U.S., according to data from the Centers for Disease Control and Prevention. The subvariants BQ.1 and BQ.1.1 now represent 27% of infections in the U.S., a significant jump from the week prior when they made up about 16% of … Read more